Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Department of Radiation Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
J Cancer Res Ther. 2023 Oct 1;19(7):1887-1892. doi: 10.4103/jcrt.jcrt_243_22. Epub 2023 Apr 24.
The goal of this study was to assess the clinicopathologic characteristics and prognostic variables in men with breast cancer (BC).
Clinical features, pathological characteristics, stage at diagnosis, and therapy data were noted. Survival analysis was performed using the log-rank technique and Cox regression model.
Eighty patients were included in the study. In 31% of the individuals, BRCA (BReast CAncer genes 1 and 2) mutations were identified. The estrogen receptor (ER) positivity ratio was 93.6%, whereas the progesterone receptor (PR) positivity ratio was 74.4%. In 16.9% of the cases, HER2 overexpression was found. The median survival time was 120.9 months (70.3-171.5), and the five-year overall survival (OS) ratio was 74.9%. In univariate analysis, BRCA mutation status had no effect on OS (P = 0.50). CA15-3 levels (P = 0.03) at diagnosis and history of smoking (P = 0.03) were significantly linked with OS. However, the multivariate analysis could not confirm these results.
We found that BRCA mutation, body mass index, a history of smoking, and alcohol consumption did not affect the OS in this research.
本研究旨在评估男性乳腺癌（BC）患者的临床病理特征和预后变量。
记录临床特征、病理特征、诊断时的分期和治疗数据。采用对数秩检验和 Cox 回归模型进行生存分析。
本研究纳入了 80 例患者。在 31%的个体中，发现了 BRCA（BReast CAncer genes 1 and 2）基因突变。雌激素受体（ER）阳性率为 93.6%，孕激素受体（PR）阳性率为 74.4%。16.9%的病例存在 HER2 过表达。中位生存时间为 120.9 个月（70.3-171.5），五年总生存率（OS）为 74.9%。在单因素分析中，BRCA 突变状态对 OS 没有影响（P=0.50）。诊断时 CA15-3 水平（P=0.03）和吸烟史（P=0.03）与 OS 显著相关。然而，多因素分析无法证实这些结果。
我们发现，BRCA 突变、体重指数、吸烟史和饮酒史在本研究中并未影响 OS。
